Drug Profile
H 1337
Alternative Names: ALY-1337; H-1337Latest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator D. Western Therapeutics Institute
- Developer Allysta Pharmaceuticals; D. Western Therapeutics Institute
- Class Antiglaucomas; Eye disorder therapies; Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glaucoma; Ocular hypertension
- Preclinical Pulmonary hypertension
Most Recent Events
- 28 Aug 2023 Phase-II clinical trials in Glaucoma (In adults, In the elderly) in USA (Ophthalmic) (NCT05913232)
- 28 Aug 2023 Phase-II clinical trials in Ocular hypertension (In the elderly, In adults) in USA (Ophthalmic) (NCT05913232)
- 22 Jun 2023 D. Western Therapeutics Institute plans phase-IIb trial for Open angle glaucoma and Ocular hypertension in USA (Ophthalmic, liquid) in September 2023 , (NCT05913232)